Related Experiment Video
Updated: Feb 17, 2026
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
Published on: June 13, 2018
Spontaneous Regression in a Patient With Infantile Fibrosarcoma
Sameer Farouk Sait1, Enrico Danzer2, Daniel Ramirez3
1Departments of Pediatrics.
Insights
Infantile fibrosarcoma, a rare pediatric tumor, may undergo spontaneous regression. This case highlights a potential benign clinical course, suggesting watchful waiting as a viable option.
Area of Science:
- Pediatric Oncology
- Molecular Pathology
- Dermatology
Background:
- Infantile fibrosarcoma is a rare soft tissue tumor typically presenting as a rapidly growing mass.
- Standard treatment often involves surgery and/or chemotherapy due to its aggressive potential.
Observation:
- A case of a 5-month-old infant with biopsy-proven and molecularly confirmed infantile fibrosarcoma of the right leg is presented.
- The tumor exhibited spontaneous regression without any signs of local recurrence by 26 months of age.
Findings:
- Review of previously reported cases suggests that some infantile fibrosarcomas may follow a benign clinical course.
- This case provides anecdotal evidence supporting the possibility of spontaneous regression in infantile fibrosarcoma.
Implications:
- The findings suggest that watchful waiting might be a reasonable alternative to aggressive treatment in select cases of infantile fibrosarcoma.
- Further research is needed to understand the mechanisms of spontaneous regression and identify predictive factors for a benign course.
Abstract:
Infantile fibrosarcoma usually presents as a rapidly growing mass on the extremities or trunk. We describe spontaneous regression in a 5-month-old female infant with biopsy proven, molecularly confirmed, right leg infantile fibrosarcoma currently at 26 months of age with no signs of local recurrence. Previously reported cases of spontaneous regression are reviewed, suggesting a benign clinical course in some cases. Although evidence for spontaneous regression is anecdotal in this rare tumor type, physicians should weigh the risks and benefits of surgery and chemotherapy against watchful waiting.
